Co-Authors
This is a "connection" page, showing publications co-authored by James Norris and Christina Johnson.
Connection Strength
0.494
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.139
-
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 Jan; 12(1):12-8.
Score: 0.126
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.103
-
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
Score: 0.098
-
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22.
Score: 0.029